1y return+110.8%S&P 500 +20.9%
3y return+151.1%S&P 500 +68.5%
5y return+131.6%S&P 500 +74.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2020: $226 against $200 in the S&P 500.2
Silverarc Capital Management, LLCS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| Ascendis Pharma A/sCUSIP K08588103 | $55.0M | 6.1% | New |
| CELCCelcuity Inc | $52.4M | 5.8% | +40.0% |
| COGTCogent Biosciences Inc | $49.6M | 5.5% | −2.5% |
| Urogen Pharma LtdCUSIP M96088105 | $47.9M | 5.3% | −13.4% |
| IMNMImmunome Inc | $42.7M | 4.8% | +9.0% |
| DNTHDianthus Therapeutics Inc | $38.0M | 4.2% | −40.4% |
| RYTMRhythm Pharmaceuticals Inc | $34.6M | 3.8% | +1.8% |
| ORKAOruka Therapeutics Inc | $33.6M | 3.7% | +133.8% |
| GLUEMonte Rosa Therapeutics Inc | $26.8M | 3.0% | −44.6% |
| SNDXSyndax Pharmaceuticals Inc | $26.5M | 3.0% | +36.6% |
| ELVNEnliven Therapeutics Inc | $24.8M | 2.8% | New |
| IMVTImmunovant Inc | $23.9M | 2.7% | +49.5% |
| ERASErasca Inc | $23.1M | 2.6% | −31.8% |
| SGMTSagimet Biosciences Inc | $22.6M | 2.5% | New |
| ABVXAbivax Sa | $22.6M | 2.5% | −43.9% |
| PRAXPraxis Precision Medicines I | $22.0M | 2.4% | −8.2% |
| KODKodiak Sciences Inc | $21.3M | 2.4% | −44.9% |
| DFTXDefinium Therapeutics Inc | $18.8M | 2.1% | New |
| VCYTVeracyte Inc | $18.7M | 2.1% | +77.0% |
| GHGuardant Health Inc | $15.0M | 1.7% | +1.3% |
| CCCCC4 Therapeutics Inc | $14.2M | 1.6% | +58.6% |
| ZBIOZenas Biopharma Inc | $12.9M | 1.4% | −55.1% |
| TRVITrevi Therapeutics Inc | $12.6M | 1.4% | +32.7% |
| Helix Acquisition Corp IIICUSIP G4444S107 | $12.5M | 1.4% | −2.6% |
| ALXOAlx Oncology Hldgs Inc | $11.9M | 1.3% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| TRVITrevi Therapeutics Inc | September 30, 2022 | +1111.0% | $12.6M |
| RYTMRhythm Pharmaceuticals Inc | June 30, 2023 | +573.3% | $34.6M |
| DNTHDianthus Therapeutics Inc | March 31, 2025 | +437.4% | $38.0M |
| GLUEMonte Rosa Therapeutics Inc | September 30, 2025 | +226.6% | $26.8M |
| Compugen LtdCUSIP M25722105 | December 31, 2022 | +199.0% | $6.8M |
| COGTCogent Biosciences Inc | September 30, 2025 | +169.5% | $49.6M |
| Urogen Pharma LtdCUSIP M96088105 | September 30, 2023 | +162.7% | $47.9M |
| CMPSCompass Pathways PLC | March 31, 2026 | +155.9% | $7.1M |
| ORICOric Pharmaceuticals Inc | June 30, 2022 | +141.7% | $8.0M |
| CELCCelcuity Inc | September 30, 2025 | +111.8% | $52.4M |
Sold off last quarter
- Kalvista Pharmaceuticals IncCUSIP 483497103 was $57.9M
- Nuvalent IncCUSIP 670703107 was $36.4M
- Ascendis Pharma A/sCUSIP 04351P101 was $28.5M
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $18.5M
- SRRKScholar Rock Hldg Corp was $16.7M
- CGONCg Oncology Inc was $11.3M
- CLDXCelldex Therapeutics Inc New was $5.7M
- CYTKCytokinetics Inc was $4.7M
- CLYMClimb Bio Inc was $4.7M
- CMPXCompass Therapeutics Inc was $4.5M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +19.6% | +14.8% |
| March 31, 2026 | +8.6% | −4.6% |
| December 31, 2025 | +24.7% | +2.4% |
| September 30, 2025 | +30.2% | +7.8% |
| June 30, 2025 | +13.7% | +10.5% |
| March 31, 2025 | −5.8% | −4.6% |
| December 31, 2024 | −10.4% | +2.1% |
| September 30, 2024 | +4.6% | +5.4% |
| June 30, 2024 | −11.8% | +4.0% |
| March 31, 2024 | +19.1% | +10.0% |
| December 31, 2023 | +27.4% | +11.2% |
| September 30, 2023 | −11.3% | −3.6% |
| June 30, 2023 | +14.7% | +8.3% |
| March 31, 2023 | −10.9% | +7.0% |
| December 31, 2022 | +9.0% | +7.1% |
| September 30, 2022 | +6.0% | −5.3% |
| June 30, 2022 | −4.3% | −16.5% |
| March 31, 2022 | −13.7% | −4.9% |
| December 31, 2021 | +0.5% | +10.7% |
| September 30, 2021 | −6.0% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Silverarc Capital Management, LLC Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1816307&type=13F-HR&dateb=&owner=include&count=40CIK 1816307
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1816307/000142050626001563/Filed August 13, 2026 · accession 0001420506-26-001563